- Reuters•4 days ago
Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly. Drugmakers believe giving patients and doctors the ability to check inhaler use in this way could be a big help in proving the value of their medicines to governments and insurers, though they need to tread carefully on data privacy. GlaxoSmithKline, AstraZeneca and Novartis are all chasing the opportunity via deals with device firms including U.S.-based Propeller Health and Australian-listed Adherium, as well as technology players like Qualcomm.
- Bloomberg•4 days ago
Indian drugmakers won U.S. approval to sell generic versions of the cholesterol pill Crestor, gaining permission to sell cheaper copies of an AstraZeneca Plc best-selling pill that brings in $7 million ...
|Bid||4,550.00 x 20700|
|Ask||4,620.00 x 15300|
|52wk Range||3,680.00 - 4,634.00|
|Day's Range||4,529.00 - 4,616.50|
|Avg Vol (3m)||2,608,685|
As of 12:13 PM EDT. Market closed.